Abstract. Plasminogen activator inhibitor-1 (PAI-1) is an important regulator of numerous pathophysiological processes such as inflammation, thrombosis, angiogenesis and tumor metastasis. Its expression is induced by hypoxia at the transcriptional level, via the hypoxia inducible factor-1 (HIF-1) or -2 (HIF-2). In this study, we elucidated the mechanism of transcriptional regulation of mouse PAI-1 gene by hypoxia in mouse hepatoma cells. We searched for hypoxia response elements (HREs) of murine PAI-1 promoter using several molecular biological assays. DNAse I hypersensitivity assay first suggested that PAI-1 gene expression is up-regulated by protein-DNA interactions at the -3.6-and -3-kb upstream regions of the PAI-1 gene transcription start site. An approximately 6.4-kb region of DNA containing the 5'-flanking promoter region of the PAI-1 gene was isolated, mapped, and cloned into reporter gene assay vectors and sequenced. Luciferase reporter gene assay subsequently identified two functional HREs, located around -3.6 kb of the 5'-flanking promoter region of PAI-1 gene that were responsible for the enhancement of luciferase reporter gene activity. Mutation of the HREs in this fragment abolished luciferase reporter gene activity. Finally, in vitro and in vivo protein-DNA interaction assays confirmed binding of the two HREs to HIF-1 or HIF-2 protein. Our results show that two HREs located around -3.6 kb of the 5'-flanking promoter region of the mouse PAI-1 gene function as hypoxia enhancers, which, alongside other regulatory regions, control PAI-1 gene transcription by HIF-1 or HIF-2 under hypoxic environments in mouse hepatoma cells.
Introduction
The stringent regulation of gene expression in response to endogenous and exogenous stimuli is fundamental to life. Aberrant gene expression resulting from toxic or otherwise undesirable stimuli may alter the balance of the biological system and lead to human diseases such as ischemia, inflammation and malignancy. The basic helix-loop-helix/Per-AhRArnt-Sim (bHLH/PAS) proteins are an important group of sensing molecules that link the environment to development and physiology by transactivating the expression of many genes (1) (2) (3) . This group of transcription factors includes the aryl hydrocarbon receptor (AhR) and its dimerization partner AhR nuclear translocator (Arnt) (1) , as well as the hypoxia inducible factor-1·, 2· and -3· (4, 5) . The physiological and pathological responses to hypoxia are mediated by the hypoxiainducible factor-1 or -2 [HIF-1 or HIF-2; a heterodimer of stabilized HIF-1· or HIF-2· and Arnt protein (also known as HIF-1ß)] in the nucleus (5, 6) . This heterodimer complex then binds to the hypoxia response element (HRE; 5'-RCGTG-3', R=A or G) to activate the transcription of >100 downstream target genes (1) . Plasminogen activator inhibitor-1 (PAI-1) is a well-known target gene induced by hypoxia (7) (8) (9) (10) (11) (12) , although the detailed mechanism(s) underlying the induction is not fully understood.
PAI-1 is a specific and potent inhibitor of urokinase type plasminogen (u-PA) and tissue-type plasminogen (t-PA) activators, and is therefore a key regulator of the fibrinolysis process (13) . However, its function is not limited to fibrinolysis, since plasmin (the active product of u-PA and t-PA catalysis) performs additional functions such as degradation of extracellular matrix and activation of growth factors (including vascular endothelial growth factor required for neovascularization) (14) . Through these systems, PAI-1 has the ability to modulate cell adhesion/migration and neovascularization; and expectedly it has been implicated in tumor invasion, metastasis and angiogenesis, processes characteristic of high-grade malignancy (15, 16) . In addition, PAI-1 was shown to inhibit apoptosis and thus promote tumor growth and aggressiveness (17) . PAI-1 may partly mediate the antiapoptotic effects of the p53 tumor suppressor and the c-myc oncogene, both of which have been reported to dysregulate the expression of PAI-1 (18, 19) . High levels of PAI-1 in tumors is consistently predictive of poor prognosis (20, 21) . Drug-resistant tumor cells appear to express increased levels of tumor markers for invasion and metastasis, including PAI-1 (22) . Thus, understanding the regulation of PAI-1 expression by hypoxic stress is relevant to important processes such as coagulation, angiogenesis and tumor metastasis.
To study the mechanisms of PAI-1 regulation by hypoxia, we used mouse hepatoma cells (Hepa1c1c7) and its Arnt -/-cells (BP r C1) because they have proven to be a powerful experimental system in our previous studies of glucose transporter 1 (Glut1) and phosphoglycerate kinase 1 (PGK1) gene regulation by hypoxia (23) . Herein, we report characterizing the murine-specific enhancer elements on the mouse PAI-1 gene to elucidate the mechanism of transcriptional control of PAI-1 gene expression by hypoxia in mouse hepatoma cells. Our data provide new insights into the mechanism of PAI-1 expression in response to hypoxic stress, which may have implications for cancer gene therapy.
Materials and methods
Cell culture. Hepa1c1c7 and BP r C1 were routinely cultured in ·-minimum essential medium, in a humidified incubator maintained at 37˚C and 95% air/5% CO 2 .
Northern blot analysis. Cells were grown to 80% confluency and exposed to hypoxia (2.0% O 2 /5% CO 2 /93% N 2 ) in an automatic CO 2 /O 2 incubator for 24 h. Un-induced cells were cultured under normoxic conditions (20% O 2 /5% CO 2 ). Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions, quantified spectrophotometrically at 260 nm and checked for integrity by electrophoresis on a 1% agarose gel. Equal amounts (10 μg) of each sample were electrophoresed on a 1% agarose formaldehyde gel and capillary transferred (in 10X SSC) onto nylon membranes overnight. RNA was then UV crosslinked onto the nylon membranes. A PAI-1 cDNA probe (786 bp, 701-1487 of the mouse PAI-1 cDNA sequence from a GenBank accession no. M33961) was labeled with [·-32 P]-dCTP using Rediprime random primer labeling kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ). Hybridization was done at 68˚C for 18 h using the Expresshyb Hybridization solution (Clontech, Mountain View, CA). Membranes were washed with 2X SSC, 0.05% SDS for 2x20 min at 55˚C, and with 0.1% SSC, 0.1% SDS for 2x20 min at 65˚C before exposing to Hyperfilm at -80˚C. Membranes were stripped of PAI-1 cDNA probes and re-probed with actin cDNA to check equality of sample loading. 6 plaques, 20 plates (150 mm) were used. The mixture was incubated for 15 min at 37˚C, mixed with 6.5 ml of top agarose and spread evenly onto a freshly poured 150-mm bottom agar plate. After 8 h incubation at 37˚C, the plates were chilled for 2 h at 4˚C. The plaques were transferred onto nylon membranes for 2 min, denatured in a solution containing 1.5 M NaCl and 0.5 M NaOH for 5 min, neutralized in a solution containing 1.5 M NaCl and 0.5 M Tris-HCl, pH 7.5 for 5 min, and rinsed in a Tris buffer (0.2 M Tris-HCl, pH 7.5)/2X SSC. Following UV-crosslinking of the DNA to the membrane for 30 sec, the membranes were prehybridized for 2 h at 60˚C, and then hybridized overnight at 60˚C with same probe used in Northern blotting. The membranes were washed with 2X SSC and 0.05% SDS for 1 h at 60˚C and then with 0.1X SSC and 0.1% SDS for 1 h at 60˚C. The membranes were exposed to X-ray film at -80˚C. Positive plaques were amplified and their DNAs were purified.
Western blot analysis.

Plasmid constructs.
An approximately 55-kb DNA fragment was isolated from lambda DASH II mouse Library and mapped by several restriction enzymes. For luciferase reporter analysis, 6.4 kb of 5'-flanking region of PAI-1 fragment was copied by PCR and ligated with 5 kb of pGL3 basic vector (Invitrogen, Carlsbad, CA) and named pGL3-5HS. In addition, pGL3-4HS and pGL3-2HS were constructed from pGL3-5HS by EcoRV digestion at -6.4 kb, XbaI at -5.4 kb and SmaI at -2.1 kb. The constructs pGL3-EX and pGL3-XS were made from pGL3-5HS by EcoRV digestion at -6.4 kb, XbaI at -5.4 kb and SmaI at -2.1 kb with the pGL3 promoter vector. The constructs pGL3-HS(-3) and pGL3-HS(-3.6) were made by the ligation of 5'-flanking region of PAI-1 fragments -3136 to -2985 bp and -3900 to -3547 bp, to the pGL3 promoter vector, respectively. Mutants pGL3-HS(-3.6)M1, pGL3-HS(-3.6)M2, pGL3-HS(-3.6)M3, pGL3-HS(-3.6)M4 and pGL3-HS(-3.6)M5 were made from pGL3-HS(-3.6) by PCR using primers designed with mutated HRE. We used the promoter of PGK1-promoter and pGL3 basic vector (pGL3-PPGK1) which consists of the HREs of the PGK-1 gene (23) ligated to the pGL3 basic vector as a positive control, and a non-functional mutant mPPGK1-pGL3 construct (pGL3-mPPGK1) as a negative control. We also used pGL3-5 (HRE), which is made from 5 random repeated HREs linked to the pGL3-promoter vector as a positive control.
Sequencing of 5'-flanking region of PAI-1 gene. By using primers of the pGL3 vector, the 5'-flanking region of the PAI-1 gene (up to about -7 kb) from the above constructs was sequenced and the sequence data were sent to DDBJ (accession no. AB331006).
Transient transfection and luciferase assay. Cells were seeded onto 6-well plates 18 h before transfection, such that cells were 50-80% confluent on the day of transfection. To each well, a total of 4 μg DNA was transfected: 1 μg pcDNA-HIF-1· or 1 μg pcDNA-HIF-2·, 0.5 μg firefly luciferase reporter plasmid, 0.1 μg pRL-TK vector plasmid (expressing Renilla luciferase, as internal standard for transfection efficiency) and 2.4 μg pUC19 (to standardize the total amount of transfected DNA). Transfection was done using SuperFect Transfection Reagent (Qiagen, Valencia, CA) according to the manufacturer's protocol. Cells were harvested 24 h after transfection and luciferase activities measured using Dual luciferase reporter assay system (Promega, Madison, WI) and a Lumat LB 9507 luminometer according to manufacturer's instructions. For studies on hypoxia inducibility, transfected cells were exposed to 2% O 2 for 24 h, then harvested for measurement of reporter gene activities. Firefly luciferasereporter gene activities were normalized to the Renilla luciferase activities. Experiments were done in triplicates.
DNAse I hypersensitivity assay. DNAse I, proteinase K, restriction endonucleases, buffer-saturated phenol and phenol:chloroform:isoamyl alcohol (25:24:1) were from Gibco BRL Life Technologies, Inc. (Gaithersburg, MD). Cells were grown to 70% confluency and treated with 2% O 2 for 4 h. Nuclei were isolated and aliquots (equivalent to 10 7 nuclei) were digested with 0-20 U/ml of DNAse I for 90 sec at 20˚C, in a total volume of 2 ml. Digestion was stopped by addition of 2 ml of stop buffer [20 mM Tris-HCl (pH 8.0), 20 mM NaCl, 20 mM EDTA, 1% sodium dodecyl sulfate (SDS), 600 μg/ml proteinase K], and genomic DNA was purified. Purified genomic DNA was quantified spectrophotometrically at 260 nm and 20 μg of each sample was restriction digested with XhoI or BstEII. Samples were purified by phenol: chloroform extraction and ethanol precipitation, and precipitated DNA pellets resuspended in water for electrophoresis on a 1% agarose gel. Fractionated DNA was then capillary transferred onto nylon membranes overnight in 10X SSC. Transferred DNA was UV crosslinked onto the nylon membranes and hybridized with a 380-bp probe (BstEII/XhoI restriction fragment) overnight at 60˚C in the Clontech Expresshyb hybridization solution. Membranes were washed to a final stringency in 0.1X SSC, 0.1% SDS at 65˚C and exposed to Hyperfilm-MP at -80˚C.
In vivo footprinting and ligation-mediated (LM)-PCR.
To demonstrate protein-DNA interactions in situ, dimethyl sulfate (DMS)-piperidine and DNAse I methods (24) were used. In the DMS modification and piperidine cleavage of genomic DNA, cells were removed from normoxic or hypoxic conditions and immediately treated with DMS (5 μl of DMS/ml of culture medium) for 90 sec at room temperature. After removing media containing DMS and washing with PBS, 2 ml of stop buffer (20 mM Tris-HCl, pH 8.0, 20 mM NaCl, 20 mM EDTA, 1% SDS, 600 μg/ml proteinase K) was added to each plate and the viscous solution was collected into a 15-ml tube containing 2 ml of dilution buffer (150 mM NaCl, 5 mM EDTA), and incubated at 37˚C for 3 h. The purified DNA was mixed with piperidine solution and incubated at 70˚C for 90 min, then dry vacuumed to evaporate piperidine. The purified DNA was then analyzed by LM-PCR. For DNAse I digestion of genomic DNA, cells under the normoxic or hypoxic conditions were removed from the incubator, and the culture medium of cells was immediately removed and replaced with 3 ml of digestion buffer (150 mM sucrose, 80 mM KCl, 35 mM HEPES, pH 7.4, 5 mM K 2 HPO 4 , 5 mM MgCl 2 , 2 mM CaCl 2 , 0.01% lysolecithin, 20 μg DNAse I/ml) at room temperature for 2.5 min. The digestion buffer was then removed and replaced with 2 ml of stop buffer. The viscous solution was collected into a tube containing 2 ml of dilution buffer, and incubated at 37˚C for 3 h. The genomic DNA was then purified and analyzed by LM-PCR as described previously (24) 
Electrophoretic mobility shift assay (EMSA)
. EMSA was performed with a gel shift assay. Briefly, complementary oligonucleotide pairs, 5'-TTCCCGGCCCCACGTACCTCA CGCTCTTATCTCTG-3' and 5'-CAGAGATAAGAGCGTG AGGTACGTGGGGCCGGGAA, corresponding to the PAI-1 promoter sequences from -3639 to -3604 were synthesized, hybridized and used as the substrate for this binding reactions. The oligonucleotide pairs were annealed and end-labeled with [Á-
32 P]-dATP using T4 polynucleotide kinase. The labeled probe was separated from unincorporated nucleotides using G-50 columns (Amersham Pharmacia Biotech, Inc., Piscataway). For the binding reactions, a total volume of 20 μl containing 5 μg nuclear extract obtained from hypoxia-treated Hepa1c1c7 cells, 30 fmol 32 P-labeled oligonucleotides, and a non-specific competitor (300 ng poly dI/dC) in a binding buffer with a final concentration of 12 mM HEPES, 4 mM Tris (pH 7.9), 60 mM potassium chloride, 1 mM EDTA, and 1 mM dithiothreitol. After incubation for 30 min at room temperature, 5 μg anti-HIF-1· (Cayman, Ann Arbor, MI) or anti-HIF-2· antibody (Santa Cruz Biotechnology) was added for supershift detection of the HIF-1 complex and incubated overnight at 4˚C. The products were analyzed by electrophoresis in 6% non-denaturing polyacrylamide gels. Electrophoresis was performed at 200 volts in 0.5X TBE buffer at 4˚C for 2 h. After electrophoresis, the gels were dried and subjected to autoradiography.
Chromatin immunoprecipitation (ChIP) assay. ChIP assay was performed using the ChIP-IT k TM (Active Motif, Carlsbad, CA), following the manufacturer's instructions, and using 2x10 7 Hepa1c1c7 or BP r C1 cells, under normoxic or hypoxic conditions. DNA-protein complexes were cross-linked in vivo with 1% final concentration of formaldehyde for 15 min at room temperature. The fixation reaction was stopped by adding Glycine Stop-Fix solution to a final concentration of 0.125 M and rocking at room temperature for 5 min. Cells were washed with ice-cold PBS and collected by centrifugation for 10 min at 2500 rpm at 4˚C. Cells were resuspended in 1.5 ml ice-cold lysis buffer (5 mM PIPES, pH 8.0, 85 mM KCl, 0.5% NP-40 and protease inhibitors) and incubated on ice for 30 min, then transferred to an ice-cold dounce homogenizer and dounced on ice with 10 strokes. Nuclei were pelleted by centrifugation for 10 min at 5,000 rpm at 4˚C followed by resuspension in 1 ml shearing buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS and protease inhibitors). Input chromatin was generated by shearing the fixed chromatin into small (200-1000 bp), uniform pieces by sonication (9 intervals of 15 sec, 2 min resets between intervals, power setting 2 with Branson 3000 sonicator). Pre-clearing was performed by incubating input chromatin with protein A/G agarose and rabbit or mouse IgG in ChIP dilution buffer (1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1 and 150 mm NaCl) for 2 h at 4˚C. DNA-protein complexes were immunoprecipitated with specific antibody from input chromatin overnight at 4˚C. Protein A/G agarose was added to precipitate the immune complexes for 5 h at 4˚C. Immunoprecipitation with IgG was used as a negative control to demonstrate antibody specificity. Immunoprecipitates were washed with a series of buffers (1 ml each wash with rocking for 10 min at 4˚C) as follows: one wash with low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl); four washes with high salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl); one wash with LiCl wash buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1); two washes with TE buffer. Immunoprecipitated DNA-protein complexes were eluted from the protein A/G agarose with 1% SDS and 0.1 M NaHCO 3 . The formaldehyde cross-links of the immunoprecipitated DNA-protein complexes were reversed by adding 5 M NaCl and 1 μl of RNase A. The cross-links were also reversed in a portion of precleared input chromatin that had not been subjected to immunoprecipitation to generate input DNA. DNA was gel-purified using a PCR purification kit (Qiagen, Valencia, CA). Input DNA (diluted 200-fold) and DNA immunoprecipitated with specific antibodies or IgG were PCRamplified using primers flanking the PAI-1 promoter primers from -3743 to -3474 bp (-3743 primer: 5'-GCAGGGGACAG TCATGGAA-3' and -3474 primer: 5'-AAAACCACTTTG ACCTCATC-3'), relative to the transcriptional start site at +1. As a negative control, two primers (5'-ATGGTTGCCA CTGGGGATCT and 5'-TGCCAAAGCCTAGGGGAAGA) for the flanking region between GAPDH and CNAP1 (chromosome condensation-related SMC-associated protein) gene were used following the manufacturer's instructions. PCR amplification was performed with an initial melt step at 94˚C for 5 min, then 24-30 cycles of 94˚C for 45 sec, 56˚C for 30 sec and 72˚C for 60 sec followed by 72˚C for 10 min. Products were analyzed by electrophoresis on a 2% agarose gel.
Results
Hypoxia induces the accumulation of PAI-1 mRNA and protein in an Arnt-dependent manner in mouse hepatoma cells. Preliminary observations indicated the induction of PAI-1 in the rat hepatocyte (8) and human hepatoma cell line HepG2 (9) in response to hypoxia. We therefore further analyzed the expression pattern of PAI-1 when exposed to hypoxia, using Arnt-positive mouse hepatoma cell line (Hepa1c1c7) and its Arnt-deficient variant (BP r C1) by Northern blotting (Fig. 1A) and Western blotting (Fig. 1B) . The PAI-1 mRNA and protein were constitutively expressed albeit at low levels in Hepa1c1c7 cells, and its expression was markedly enhanced after exposure to hypoxia (2% O 2 ) for 24 h. Hypoxia induced the accumulation of PAI-1 mRNA and protein via an Arnt-dependent mechanism (Fig. 1A and  B) : PAI-1 mRNA and protein were induced in Hepa1c1c7 cells exposed to hypoxia, whereas this induction was not observed in BP r C1 (Arnt -/-) cells. Thus, as with the regulation of other hypoxia-activated genes (25) , Arnt (HIF-1ß) is an absolute requirement for PAI-1 induction by hypoxia. In the BP r C1 (Arnt -/-) cells, the absence of the critical partner Arnt abolished the hypoxia-induced PAI-1 expression.
DNAse I-hypersensitive sites were identified in the 5'-upstream promoter region of PAI-1 gene in response to normoxia and hypoxia. We used the DNAse I hypersensitivity technique to find protein-DNA interaction sites on the promoter region of the mouse PAI-1 gene. This technique is based on the assumption that proteins binding to the response elements will alter the chromatin structure in such a way as to increase the susceptibility of neighbouring regions to cleavage by DNAse I. Genomic Southern blotting identified a 20-kb XhoI band 5'-upstream of the transcription start site ( Fig. 2A and  C) . Thus, we used this restriction enzyme to determine the presence of hypersensitive site (HS) (26) within this ~20 kb of the PAI-1 gene. Using XhoI (Fig. 2A) , three HSs (marked as HS1, HS2 and HS3) were detected at about -3, -3.6 and -6 kb 5'-upstream of the transcription start site in un-induced, or hypoxia-induced Hepa1c1c7 cells, respectively, suggesting that these sites are important in both basal and inducible expression of the constitutively expressed PAI-1 gene. Moreover, enhanced protein-DNA interactions were observed at -3.6 and -3 kb in the hypoxia-induced cells ( Fig. 2A) , indicating the likely occupancy of HIF-1 in these two regions in response to hypoxia. Using BstEII digestion, two HS sites (HSa and HSb) were observed at about -1.1 and -1.3 kb 5'-upstream of the transcription start site in un-induced and hypoxia-induced Hepa1c1c7 cells, suggesting that no additional protein-DNA interaction occurs at these sites under hypoxic conditions (Fig. 2B) . The HSa and HSb sites likely correspond to regions flanking the Sp1 and ßHLTF (helicase-like transcription factor) sites (27) , indicating protein occupancy at these DNA motifs in the un-induced and induced states. No HS site was detected in the 3'-region of PAI-1 gene examined (data not shown). These results suggest that DNAse I HSs at -3.6 kb and -3 kb of the 5'-flanking promoter region of PAI-1 gene are important for inducible expression of the PAI-1 gene under hypoxia.
The presence of functional HREs on the promoter region of mouse PAI-1 gene in Hepa1c1c7 cells.
We cloned a series of the PAI-1 promoter fragments encompassing the HS sites and subcloned them into the luciferase reporter gene assay vector. The plasmids were called pGL3-5HS, pGL3-4HS and pGL3-2HS and used for determining functional HRE(s) on the PAI-1 promoter region in response to hypoxia (Fig. 3) . As sequences beyond the -1 kb region of PAI-1 gene were not available, a large piece of phage DNA containing the PAI-1 gene (55 kb) was isolated by using lambda plague screening assay with the mouse lambda genomic library and a probe described in the Materials and methods. For the functional analysis of these PAI-1 constructs in the Hepa1c1c7 cells, we used the luciferase reporter assay to test the endogenous HIF activity induced in hypoxia against these reporter constructs (Fig. 3) . As a positive control, we used the promoter of PGK1 and pGL3 basic vector (pGL3-PPGK1) which consists of the HREs of the PGK-1 gene ligated to the pGL3 basic vector since HIF has been reported to bind to the HREs of PGK-1 in the Hepa1c1c7 cells under hypoxia (23) . As a negative control, a non-functional mutant mPPGK1-pGL3 construct (pGL3-mPPGK1) was used since it could not associate with HIF protein. The pGL3-4HS construct, containng four HSs at -3.6, -3, -1.3 and -1.1 kb, showed the highest induction of luciferase activity. The pGL3-5HS and pGL3-2HS constructs, containing five HSs and two HSs respectively, did not show greater luciferase activity than pGL-4HS, indicating that HSs at -6, -1.3 and -1.1 were less important sites for protein-DNA interactions under hypoxia (Fig. 3) . We therefore infer that the DNAse I HSs at -3.6 and -3 kb are most critical for hypoxia-induced reporter gene activity, consistent with the result of the DNAse I hypersensitivity assay (Fig. 2A) .
-3.6-and -3-kb promoter regions of PAI-1 gene contain enhancer activity in Hepa1c1c7 cells under hypoxia.
Because the tested 5'-flanking promoter region of PAI-1 gene (pGL3-4HS) showed the greatest luciferase activity under hypoxia (Fig. 3) , this region might contain regulatory elements important for hypoxia-induced gene expression. We therefore sequenced the region between the EcoRV (-6.4 kb) and XhoI sites (-0.3 kb) at the 5'-promoter region of the PAI-1 gene and identified putative consensus sequences for HREs (RCGTG, R=A/G). According to our sequence (DDBJ accession no. AB331006), a total of seven putative HREs could be found from -3845 to -3000 bp (Fig. 4A) . To further analyze these putative HREs, this DNA fragment and two shorter DNA fragments (from -6.4 to-5.4 kb and -3136 to -2985 bp), each containing different putative HREs were made by PCR, and each ligated with pGL3 promoter vector to give pGL3-EX, pGL3-XS, pGL3-HS(-3) and pGL3-HS(-3.6) (Fig. 4B) . To distinguish which HIF molecule activates the putative HREs, HIF-1 or HIF-2 expression vector was used in an overexpression system. The plasmid constructs with greater luciferase activity with HIF-1or HIF-2 overexpression vector were pGL3-XS and pGL3-HS(-3.6) (Fig. 4B) . The pGL3-HS(-3) and pGL3-EX constructs that lack HRE elements did not show markedly enhanced luciferase activity (~1.5-fold induction) despite having putative HREs. Therefore, the DNAse I HS at -3.6 kb possesses enhancer activity in response to HIF-1 or HIF-2 under hypoxia.
To identify which of the HREs within pGL3-HS(-3.6) has transcriptional enhancing activity, four mutants (RCGTG➝ TTTTG) were constructed [HS(-3.6)M1, HS(-3.6)M2, HS (-3.6)M3, HS(-3.6)M4 and HS(-3.6)M5] and each ligated with pGL3 promoter (Fig. 4B) . The relative luciferase activities of pGL3-HS(-3.6)M1, pGL3-HS(-3.6)M2 and HS(-3.6)M5 were significantly reduced compared to that of pGL3-3.6HS, pGL3-HS(-3.6)M3 and HS(-3.6)M4. Therefore, the two HREs located at -3625 and -3616 are essential for inducing PAI-1 gene expression under hypoxia. 
HIF-1 or HIF-2 protein associate with HREs at -3625 and -3616 bp of PAI-1 gene.
To confirm any association between HIF-1 protein and the functional HREs identified through our reporter gene assays, we characterized protein-DNA interactions in situ by LM-PCR mediated in vivo footprinting (Fig. 5) , EMSA and ChIP assays (Fig. 6 ). Hepa1c1c7 and BP r C1 cells cultured under normoxia or hypoxia were treated with DMS-piperidine (lanes 1-5) or DNAse I (lanes 6-10), and their DNAs were isolated for LM-PCR. The amplified products of LM-PCR were analyzed using 8% sequencing gels. Naked genomic DNA treated with both agents in vitro was analyzed as controls (lanes 1 and 6). In lanes 2 and 3, we observed typical footprinting patterns in Hepa1c1c7 cells cultured under hypoxia compared to those cultured under normoxia. The footprints produced by DMS-piperidine represent the HREs (lane 3). The use of DNAse I generated a similar, but broader footprinting pattern (lane 8) compared to that produced by DMS-piperidine; the sequence of the footprint is shown in Fig. 5B . In the BP r C1 cells cultured under normoxia or hypoxia, the typical footprinting patterns were not observed in either the DMS-piperidine (lanes 4 and 5) or DNAse I (lanes 9 and 10) method, suggesting that HIF proteins are not involved in the occupancy of the HRE sites in BP r C1 cells. In order to investigate which HIF protein is involved in binding to the identified HREs, EMSA with antibody supershift assay was carried out (Fig. 6A) . We observed that the transcription factors ATF and CREB bind constitutively to the probe (lanes 1, 2 and 3) (28). The decreased intensities of the HIF band in lanes 2 and 3 suggest that both HIF-1 and HIF-2 proteins bound to the probe; in particular the strongly supershifted band in lane 2 suggest that HIF-2 is the predominant protein responsible for HIF/HRE interaction at -3625 and -3616 bp of PAI-1 promoter.
To further demonstrate the in vivo significance of HIF proteins and its binding to the HRE of the PAI-1 promoter, ChIP assay (Fig. 6B) was performed with antibodies recognizing HIF-1· or HIF-2·. DNA was amplified with primers from -3743 to -3474 bp that includes HREs at -3625 and -3616 bp of PAI-1 gene. Some PCR product with HIF-1· and HIF-2· antibodies were detectable in Hepa1c1c7 cells under normoxia and hypoxia, but levels markedly increased under hypoxia, especially with HIF-2· antibody,which is consistent with EMSA data. No PCR product was detectable in the BP r C1 cells under normoxia or hypoxia. In addition, no PCR product was amplified using control antibody or at a flank region between GAPDH and CNAP1 gene, demonstrating specificity. Taken together, our in vitro and in vivo data provide evidence that the two HREs at -3625 and -3616 bp of PAI-1 promoter can interact with both HIF-1 and HIF-2.
Discussion
Ischemia, inflammation and cancer give rise to low oxygen tension (hypoxia), which leads to the activation of HIF-1 or HIF-2 transcription factor in mammals. These HIF proteins act as transcriptional regulators that associate with HRE and control the expression of multiple genes involved in glycolysis (e.g. PGK and LDHA), apoptosis (e.g. BNIP3), proliferation (e.g. TGF· and CCD1), de-differentiation (e.g. Oct 4), angiogenesis (e.g. VEGF, Ang2, Fit1, Tie2) and invasion and metastasis (e. g. PAI-1, CXCR4, MMP2, Lox) (1) .
In this report, we identified the enhancer elements essential in the hypoxia-mediated induction of PAI-1 gene expression in mouse Hepa1c1c7 cells using a combination of DNAse I hypersensitivity analysis and protein-DNA interaction analysis. The induction of PAI-1 under hypoxia (7, 8, 12, 29, 30) together with a possible mechanism of its induction (8, 9, 31) has been reported. Previous reports using reporter gene assay and EMSA revealed that the -175/-158-bp region of the rat PAI-1 promoter (8) and the -194/-187-bp region of the 1-3) . Lanes 4 and 5 showed that a 500-fold (lane 4) and 250-fold (lane 5) excess of the indicated unlabeled (cold) oligonucleotide encompassing the HREs of PAI-1 was added. (B and C) Specific DNA/protein complexes were immunoprecipitated from cross-linked chromatin using a specific anti-HIF-1· or anti-HIF-2 antibody and eluted DNA was PCR-amplified using the primer set described in Materials and methods. DNA eluted from unprecipitated chromatin was used as input DNA. As a negative control, the flank region between GAPDH and CNAP1 gene was used. N, normoxia; H, hypoxia.
human PAI-1 promoter (9,31) have functional HREs that can interact with HIF-1 to enhance PAI-1 expression. Analysis of the reported mouse fibroblast PAI-1 gene sequence with the rat and human PAI-1 gene sequence shows that these HREs are conserved (8, 9) . Our study extends previous observations by identifying additional HREs in the promoter of the PAI-1 gene.
We first wanted to confirm the presence of the reported HREs in our mouse hepatoma cell line to characterize the core promoter of the PAI-1 gene in our cell system. However, our experiments showed that the HREs in this region of the mouse PAI-1 gene did not interact with HIF-1 protein (data not shown) and did not enhance luciferase activity in the reporter gene assay (Fig. 3, pGL3-2HS ). These negative data imply that the conserved HREs might be non-functional in the mouse or Hepa1c1c7 cells for unknown reasons; therefore, functional HREs of the mouse Hepa1c1c7 cells might reside further upstream or downstream of these regions.
In order to find additional HRE(s), we used the DNAse I hypersensitivity assay to locate regions of the PAI-1 promoter that may be involved in the expression of PAI-1. We identified five HSs at about -1.1, -1.3, -3, -3.6 and -6 kb 5'-upstream of the transcription start site in un-induced and hypoxia-induced Hepa1c1c7 cells, suggesting these sites to be important in both basal and inducible expression of PAI-1. Two of these HS sites, at 1.1 and 1.3 kb 5'-upstream of the transcription start site, correspond to regions flanking the Sp1 and ßHLTF sites, indicating protein occupancy at these DNA motifs in the un-induced and induced states. We observed basal PAI-1 expression under normoxia consistent with results stating that functional interactions at the Sp1 and ßHLTF sites are essential for PAI-1 expression (27) . Of particular interest are the HS sites at -3 and -3.6 kb 5'-upstream of the transcription start site: while they are also present under normoxia, these sites are enhanced under hypoxia. This suggests that the putative HREs of the PAI-1 gene may be constitutively occupied and maintained in an accessible configuration which does not undergo major chromatin remodeling when stimulated by hypoxia, but increased protein-DNA interactions may occur under hypoxia.
Luciferase reporter gene assay with PAI-1 fragments suggested that the -3.6-kb region of the PAI-1 gene was able to enhance luciferase activity. Sequence analyses show the presence of a pair of contiguous HREs (-3633 GCCCCACG TACCTCACGCTCTTA -3611) in the mouse -3.6-kb region of PAI-1 promoter. Mutation of either one or both HRE sites within the tested plasmid [pGL3-HS(-3.6)] resulted in complete loss of enhancer function. Therefore, both HREs within this -3.6-kb region of PAI-1 gene are essential for regulating mouse PAI-1 expression in response to hypoxia. In order to understand the molecular mechanism(s) leading from HIF proteins occupancy to transcription of the PAI-1 gene product, in vivo footprinting and in vivo ChIP assays were carried out at the -3.6-kb regions. The advantages of these assays are that they allow detection of protein-DNA interactions on endogenous genes in intact cells, and reflect gene regulation under in vivo conditions such as chromatin structure, and other regulatory macromolecules (32, 33) . Our data demonstrated that HIF protein/HRE interactions can only occur in the Hepa1c1c7 cells, but not in the BP r C1 cells, implying that the two HREs at the -3.6-kb region of PAI-1 promoter must be functional HREs. Although evolutionary conservation is a common criterion for the identification of functional regulatory elements, sequence comparisons in the identified HRE loci performed among mammals indicated that the identified HREs are conserved only in rodents, but not in humans or other mammals (Fig.7) . Whatever the mechanism(s) by which HREs are lost or mutated among species, it appears that the identified HREs may be essential for gene regulation in response to hypoxia only in rodent and not in other species. This poses interesting question related to cancer therapy and evolutionary changes among species in response to hypoxia.
The expression of PAI-1 gene under normoxia and hypoxia varies among cell lines (8, 29, 30, 34) . The mouse hepatoma (Hepa1c1c7) and its Arnt-deficient variant (BP r C1) cells provide a useful system for our study because PAI-1 mRNA and protein were observed in Hepa1c1c7 cells under normoxia and hypoxia, but was not observed in the BP r C1 cells. The mechanism of PAI-1 expression under normoxia is mediated by interactions between SP1 or SP3 and the helicase-like transcription factor, homologous to chromatin remodeling proteins (27) . Under normoxia, two prolines of HIF-1· oxygen-dependent degradation domain (ODD) are hydroxylated by a family of oxygen-dependent proline hydroxylases, which then associate with von Hippel-Lindau (VHL) protein and are degraded via the ubiquitin pathway (5, 35, 36) . This does not occur under hypoxia, thereby stabilizing the HIF-1· or HIF-2· proteins and allowing it with HIF-ß to recruit p300/CBP for chromatin remodeling and leading to the expression of target genes (37) . Therefore, interaction of HIF-1 or HIF-2 with the HRE is required for the induction of PAI-1 expression under hypoxia. In our system, although HIF-2· appears to be more strongly bound to the identified HREs than HIF-1·, both HIF-1 and HIF-2 seem to be involved in PAI-1 transcription. Consistently HIF-2 was reported to primarily regulate PAI-1 transcription in response to hypoxia in MCF-7 (38) and A549 cells (39) .
Hypoxia is prevalent in solid tumors, and the activity of HIF proteins in response to hypoxia regulates multiple genes that enhance tumor metastasis and angiogenesis. Thus, the disruption of the HIF signaling pathway has been studied as an attractive strategy for cancer therapy (40) . A dominant negative HIF-1· has been shown to reduce tumorigenicity of pancreatic cancer (41) . In addition, many small molecular inhibitors of the HIF signaling pathway have been discovered and used to inhibit the expression of HIF target genes to reduce angiogenesis and metastasis (42) . Another approach involves the direct inhibition of p300/CBP (43) and DNA binding activity (44) to repress the HIF target genes. Thus, the newly identified HREs in hepatoma cells might provide a good model to study cancer treatment.
In conclusion, we have identified two HREs at -3.6 kb of the 5'-flanking promoter region of the PAI-1 gene that can function as cis-acting elements to regulate PAI-1 gene induction by hypoxia. We also provided evidence of interaction of these HREs with HIF-1 or HIF-2 protein, which helps to explain the mechanism of how HIF-1or HIF-2 mediates PAI-1 gene transcription in the mouse hepatoma cells. Given the importance of hypoxia, HIF-1, HIF-2 and PAI-1 in solid tumors, the targeting of this signaling pathway offers a potentially valuable strategy for the clinical management of these tumors.
